Partner
Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510
REVOLUTION Medicines, Inc.
PR-M11-19-NI-004Nov 05, 2019
Financing
REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers
REVOLUTION Medicines, Inc.
PR-M07-19-NI-034Jul 15, 2019